Combiver(100 mcg+20 mcg)/puff

Combiver is a combination bronchodilator used to relieve bronchospasm (airway narrowing) in patients with obstructive airway disease. It combines a short-acting beta2-agonist (salbutamol) with a short-acting anticholinergic (ipratropium bromide) that work by complementary mechanisms to produce greater bronchodilation than either agent alone.

Established / Approved Uses

• Chronic Obstructive Pulmonary Disease (COPD): Maintenance and on-demand relief of bronchospasm in patients with COPD (chronic bronchitis and emphysema) who require regular treatment with more than one bronchodilator.

Guideline-Supported / Adjunct Uses

• Acute severe asthma exacerbation (adjunct therapy): Combiver is commonly used in emergency and hospital settings as an adjunct to a short-acting beta2-agonist for acute asthma exacerbations, in line with asthma management guidelines (e.g., GINA). It is used alongside, not as a replacement for, primary short-acting beta2-agonist therapy and systemic corticosteroids where indicated.
• Acute exacerbation of COPD: Nebulized Combiver is frequently used for rapid relief of bronchospasm during acute COPD exacerbations, alongside other guideline-directed therapy.

Combiver is not a rescue medication for sudden, severe shortness of breath outside of medical supervision unless specifically prescribed for that purpose by a physician.

Each formulation of Salbutamol + Ipratropium Bromide combines two active ingredients:

• Salbutamol (as sulfate): a short-acting beta2-adrenergic receptor agonist (SABA).
• Ipratropium Bromide: a short-acting muscarinic antagonist (SAMA), a quaternary ammonium anticholinergic compound.

Common strengths include nebulizer solution containing salbutamol 2.5 mg (as sulfate) with ipratropium bromide 0.5 mg per 2.5-3 mL unit-dose vial, and metered-dose inhaler formulations delivering a fixed dose of each component per actuation. Exact strengths vary by brand and dosage form; refer to the specific product label.

Combiver is a fixed-dose combination bronchodilator supplied as a nebulizer solution and/or metered-dose inhaler (MDI) for oral inhalation. It is used in the management of reversible bronchospasm associated with obstructive airway disease, most commonly chronic obstructive pulmonary disease (COPD).

The combination pairs a beta2-agonist bronchodilator that relaxes bronchial smooth muscle with an anticholinergic bronchodilator that blocks vagally-mediated bronchoconstriction, giving a broader and often more effective bronchodilator response than either drug alone, particularly in COPD.

Combiver belongs to the therapeutic class of combination bronchodilators, specifically a short-acting beta2-adrenergic agonist (SABA) combined with a short-acting anticholinergic/antimuscarinic agent (SAMA), used in respiratory medicine for obstructive airway disease.

Salbutamol + Ipratropium Bromide produces bronchodilation through two complementary and independent mechanisms:

• Salbutamol is a selective beta2-adrenergic receptor agonist. It stimulates beta2 receptors on bronchial smooth muscle, activating adenylate cyclase and increasing intracellular cyclic AMP (cAMP), which relaxes bronchial smooth muscle and produces rapid bronchodilation, typically within 5-15 minutes, lasting 4-6 hours.
• Ipratropium Bromide is a quaternary anticholinergic that competitively blocks acetylcholine at muscarinic (M1, M2, M3) receptors on bronchial smooth muscle, inhibiting vagally-mediated bronchoconstriction. Its onset is slightly slower (within 15 minutes, peak effect 1-2 hours) with a duration of up to 4-6 hours. Because it is poorly absorbed systemically, it has minimal systemic anticholinergic effects at inhaled doses.

Used together, Salbutamol + Ipratropium Bromide provides additive bronchodilation with a broader therapeutic effect than either component individually, which is particularly useful in COPD, where both cholinergic tone and beta-adrenergic responsiveness contribute to airway obstruction.

Combiver is administered by oral inhalation only, either via a jet nebulizer (nebulizer solution) or a metered-dose inhaler. It must not be swallowed or injected. Patients should be shown correct inhaler/nebulizer technique by a healthcare provider or pharmacist to ensure adequate drug delivery to the lungs. Care should be taken to avoid spraying or nebulizing the mist directly into the eyes, as this can precipitate acute eye problems (see Precautions).

The following clinically significant interactions have been established for Combiver:

• Beta-blockers (especially non-selective, e.g., propranolol): may antagonize the bronchodilator effect of the salbutamol component; concomitant use should generally be avoided in patients with obstructive airway disease unless there are compelling reasons.
• Other sympathomimetic/beta-agonist medicines: concurrent use with other beta-adrenergic agonists may potentiate cardiovascular side effects (tachycardia, palpitations) of the salbutamol component.
• Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants: may potentiate the cardiovascular effects of the salbutamol component; use with caution, including within 2 weeks of MAOI discontinuation.
• Non-potassium-sparing diuretics (e.g., thiazides, loop diuretics): the hypokalemic effect of the salbutamol component may be potentiated; monitor serum potassium if used concurrently, especially at higher doses.
• Other anticholinergic medicines: concurrent use with other inhaled or systemic anticholinergic drugs may increase the risk of anticholinergic side effects (e.g., dry mouth, urinary retention) from the ipratropium component.

Reported side effects of Combiver include those attributable to each component:

Common

• Tremor, nervousness, headache
• Tachycardia, palpitations
• Dry mouth, throat irritation, cough
• Dizziness, nausea

Less Common / Serious

• Paradoxical bronchospasm (sudden worsening of wheeze after use) — discontinue immediately and seek medical attention
• Hypersensitivity reactions, including urticaria, angioedema, or rash
• Blurred vision, eye pain, or precipitation of acute narrow-angle glaucoma if mist contacts the eyes
• Urinary retention, particularly in patients with pre-existing bladder outlet obstruction
• Hypokalemia (low blood potassium), particularly with high or frequent doses
• Cardiac arrhythmias in susceptible individuals

Pregnancy: There are no adequate and well-controlled studies of Combiver in pregnant women. It should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus. Salbutamol may theoretically inhibit uterine contractions if used near term; use during labor should be under close medical supervision. Consult a physician before use in pregnancy.

Lactation: It is not known whether the components of Combiver are excreted in human breast milk. Because many drugs are excreted in breast milk, caution should be exercised and a physician consulted before use while breastfeeding, weighing the benefit of treatment against potential risk to the infant.

The following precautions apply to the use of Combiver:

• Paradoxical bronchospasm: as with other inhaled bronchodilators, Combiver can cause paradoxical bronchospasm; discontinue immediately if this occurs and seek alternative therapy.
• Narrow-angle glaucoma: avoid allowing the nebulized mist or inhaler spray to contact the eyes, as this may precipitate or worsen acute narrow-angle glaucoma (eye pain, blurred vision, halos around lights, red eye); use a mouthpiece rather than a facemask where possible, especially in patients at risk.
• Bladder outlet obstruction / prostatic hyperplasia: use with caution due to risk of urinary retention.
• Cardiovascular disease: use with caution in patients with coronary insufficiency, arrhythmias, or hypertension, as the salbutamol component can affect heart rate and blood pressure.
• Diabetes mellitus and hyperthyroidism: use with caution; salbutamol may worsen glycemic control and may exacerbate symptoms of hyperthyroidism.
• Hypokalemia risk: caution is advised with concomitant use of diuretics, xanthine derivatives, or corticosteroids, or in states of hypoxia, as these may increase the risk of salbutamol-associated hypokalemia.
• Soya/peanut allergy: see Contraindications for formulations containing soya lecithin.

Overdose with Combiver may produce exaggerated effects of its components, including tachycardia, palpitations, tremor, nervousness, hypertension or hypotension, arrhythmias, seizures, hypokalemia, dry mouth, blurred vision, and urinary retention.

If an overdose is suspected, seek immediate medical attention or contact a poison control center right away. Treatment is supportive and symptomatic; a physician may consider a cardioselective beta-blocker with extreme caution in life-threatening situations, bearing in mind the risk of inducing bronchospasm. Do not attempt to manage a suspected overdose at home without medical guidance.

Store at room temperature (below 30°C), protected from light and moisture. Do not freeze. Keep nebules in their foil pouch until immediately before use, and discard any unused solution. Keep out of reach of children.

Elderly: No dose adjustment is generally required, but elderly patients, particularly those with cardiovascular disease, prostatic hyperplasia, or glaucoma, should use Combiver with caution and closer monitoring (see Precautions).

Renal impairment: No specific dose adjustment is established; use with the usual caution applicable to inhaled bronchodilators.

Hepatic impairment: No specific dose adjustment is established for Combiver, as it is administered by inhalation with minimal systemic metabolism.

Pediatric: Safety and efficacy of the fixed-dose combination have not been formally established for routine outpatient pediatric use; use in children, when required for acute severe exacerbations, should be directed and supervised by a pediatrician.

In COPD, Combiver is often used long-term as part of ongoing maintenance therapy, as prescribed by a physician, with periodic reassessment of respiratory status. In acute exacerbations of asthma or COPD, it is used short-term, typically over hours to a few days, until the exacerbation resolves, per physician guidance. Treatment duration should always be individualized and not exceed what is prescribed.

Salbutamol + Ipratropium Bromide belongs to the drug class of combination respiratory bronchodilators: a short-acting beta2-adrenergic agonist (SABA) combined with a short-acting muscarinic antagonist (SAMA/anticholinergic bronchodilator).

Salbutamol + Ipratropium Bromide works via two complementary mechanisms: salbutamol stimulates beta2-adrenergic receptors on bronchial smooth muscle to increase cAMP and cause bronchodilation, while ipratropium bromide blocks muscarinic acetylcholine receptors to inhibit vagally-mediated bronchoconstriction. Together they produce more complete bronchodilation than either agent alone, particularly beneficial in COPD.

C

The fixed-dose combination Combiver has not been formally established as safe and effective for routine outpatient use in children. In emergency settings, nebulized combination therapy is sometimes used off-label for severe pediatric asthma exacerbations under direct physician supervision, with dosing individualized by weight and age. Parents/caregivers should never use Combiver in a child without explicit medical direction.